Acute Respiratory Infection Clinical Trial
Official title:
Kent State University / Price Chopper Wellness Promotion Study
NCT number | NCT03454009 |
Other study ID # | 18-052 |
Secondary ID | |
Status | Completed |
Phase | N/A |
First received | |
Last updated | |
Start date | February 5, 2018 |
Est. completion date | May 11, 2018 |
Verified date | April 2019 |
Source | Kent State University |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
This is a comprehensive randomized cluster hand-hygiene improvement intervention to reduce:
self-reported acute respiratory tract infections (ARI) / influenza-like-illness (ILI) and
gastrointestinal (GI) illness, absenteeism, presenteeism; and related behavioral and
attitudinal change over a 90 day trial. The Intervention group will receive hand hygiene
supplies, and a variety of educational materials, including environmental posters in common
areas. The control group will perform their usual hygiene activities and will not receive an
intervention.
Identical weekly surveys will be administered to the intervention and control groups to
measure self-reported illness, absenteeism, presenteeism, along with behavior and attitudes
measured at specified intervals during the study. The intervention and control groups were
randomized by work floors before the onset of the enrollment period. It is hypothesized that
employees in the intervention group will experience reduced self-reported illness,
absenteeism and presenteeism along with improved protective hygiene behaviors and related
attitudes, relative to those in the control group over the 90-day trial.
Status | Completed |
Enrollment | 195 |
Est. completion date | May 11, 2018 |
Est. primary completion date | May 11, 2018 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria: - At least 18 years or older - No known allergies to alcohol or surface disinfecting wipes; - Works at least 30% of office hours at the study host site; - Consent to receiving emails from Kent State University. Exclusion Criteria: - Under 18 years of age; - Known allergies to alcohol or surface disinfecting wipes; - Works less than 30% of office hours at the study host site; - Does not consent to receiving emails from Kent State University. |
Country | Name | City | State |
---|---|---|---|
United States | The Golub Corporation (Price Chopper / Market 32) | Schenectady | New York |
Lead Sponsor | Collaborator |
---|---|
Kent State University | Cascades Tissue Group, The Golub Corporation, Price Chopper / Market 32 |
United States,
Aiello AE, Coulborn RM, Perez V, Larson EL. Effect of hand hygiene on infectious disease risk in the community setting: a meta-analysis. Am J Public Health. 2008 Aug;98(8):1372-81. doi: 10.2105/AJPH.2007.124610. Epub 2008 Jun 12. — View Citation
Arbogast JW, Moore-Schiltz L, Jarvis WR, Harpster-Hagen A, Hughes J, Parker A. Impact of a Comprehensive Workplace Hand Hygiene Program on Employer Health Care Insurance Claims and Costs, Absenteeism, and Employee Perceptions and Practices. J Occup Environ Med. 2016 Jun;58(6):e231-40. doi: 10.1097/JOM.0000000000000738. — View Citation
Baicker K, Cutler D, Song Z. Workplace wellness programs can generate savings. Health Aff (Millwood). 2010 Feb;29(2):304-11. doi: 10.1377/hlthaff.2009.0626. Epub 2010 Jan 14. — View Citation
Boyce JM, Pittet D; Healthcare Infection Control Practices Advisory Committee. Society for Healthcare Epidemiology of America. Association for Professionals in Infection Control. Infectious Diseases Society of America. Hand Hygiene Task Force. Guideline for Hand Hygiene in Health-Care Settings: recommendations of the Healthcare Infection Control Practices Advisory Committee and the HICPAC/SHEA/APIC/IDSA Hand Hygiene Task Force. Infect Control Hosp Epidemiol. 2002 Dec;23(12 Suppl):S3-40. — View Citation
Centers for Disease Control and Prevention. How flu spreads. Updated October 5, 2017: https://www.cdc.gov/flu/about/index.html
Centers for Disease Control and Prevention. Key facts about seasonal flu vaccine. Updated October 30, 2017: https://www.cdc.gov/flu/protect/keyfacts
Fendrick AM, Monto AS, Nightengale B, Sarnes M. The economic burden of non-influenza-related viral respiratory tract infection in the United States. Arch Intern Med. 2003 Feb 24;163(4):487-94. — View Citation
Hübner NO, Hübner C, Wodny M, Kampf G, Kramer A. Effectiveness of alcohol-based hand disinfectants in a public administration: impact on health and work performance related to acute respiratory symptoms and diarrhoea. BMC Infect Dis. 2010 Aug 24;10:250. doi: 10.1186/1471-2334-10-250. — View Citation
Molinari NA, Ortega-Sanchez IR, Messonnier ML, Thompson WW, Wortley PM, Weintraub E, Bridges CB. The annual impact of seasonal influenza in the US: measuring disease burden and costs. Vaccine. 2007 Jun 28;25(27):5086-96. Epub 2007 Apr 20. — View Citation
Savolainen-Kopra C, Haapakoski J, Peltola PA, Ziegler T, Korpela T, Anttila P, Amiryousefi A, Huovinen P, Huvinen M, Noronen H, Riikkala P, Roivainen M, Ruutu P, Teirilä J, Vartiainen E, Hovi T. Hand washing with soap and water together with behavioural recommendations prevents infections in common work environment: an open cluster-randomized trial. Trials. 2012 Jan 16;13:10. doi: 10.1186/1745-6215-13-10. — View Citation
Stedman-Smith M, DuBois CL, Grey SF, Kingsbury DM, Shakya S, Scofield J, Slenkovich K. Outcomes of a pilot hand hygiene randomized cluster trial to reduce communicable infections among US office-based employees. J Occup Environ Med. 2015 Apr;57(4):374-80. doi: 10.1097/JOM.0000000000000421. — View Citation
Stedman-Smith M, DuBois CL, Grey SF. Hand hygiene performance and beliefs among public university employees. J Health Psychol. 2015 Oct;20(10):1263-74. doi: 10.1177/1359105313510338. Epub 2013 Nov 20. — View Citation
World Health Organization Writing Group, Bell D, Nicoll A, Fukuda K, Horby P, Monto A, Hayden F, Wylks C, Sanders L, van Tam J. Non-pharmaceutical interventions for pandemic influenza, national and community measures. Emerg Infect Dis. 2006 Jan;12(1):88-94. — View Citation
* Note: There are 13 references in all — Click here to view all references
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Reduction in ARI/ILI/GI infections as Self-Reported in Questionnaire | The content in this measurement item has demonstrated acceptable validity and reliability in a previous study from a scale that does not have a formal title, utilized by Stedman-Smith, DuBois and Grey (2012). The scale measures whether or not participants have had self-reported (1) acute respiratory tract / influenza-like infections (ARI/ILI) or (2) gastrointestinal (GI) infections with definitions used from the Centers for Disease Control and Prevention (CDC). Measurements will occur baseline, and once per week for 12 successive weeks until the end of the trial. The number of all self-reported infections during the 3-month trial will be counted, combined and summed in the intervention and the control groups; each sum will be used to compute incidence rates and an incidence rate ratio with a 95% confidence interval (CI). | Approximately 90 days | |
Primary | Reduction in Absenteeism as Self-Reported in Questionnaire | Survey measurements will occur at baseline, and once per week for 12 successive weeks until the end of the trial. The content in this measurement item has demonstrated acceptable validity and reliability in a previous study from a scale that does not have a formal title, utilized by Stedman-Smith, DuBois and Grey (2012). The item contains a 6-point scale from zero days lost (0) to more than 5 days lost (6). The question was slightly adapted to add the response option of missing ½ day of work. The total number of lost work-days will be counted and summed from the 12 weekly surveys in the intervention and control group. Incidence rates and an incidence rate ratio with a 95% confidence interval will be calculated. Person days observed for this measurement will exclude holidays and weekends to match the intent of the survey regarding missed scheduled work-days. | Approximately 90 days | |
Primary | Reduction in Presenteeism as Self-Reported in Questionnaire | Survey measurements will occur at baseline and once per week for 12 successive weeks until the end of the trial. This measurement is based upon 3 items on the Stanford Presenteeism Scale (SPS). Each of the 3 items are measured on a scale of 1-5 points from strongly agree (1 point) to strongly disagree (5 points). The original SPS construct measured these same items from a scale of strongly disagree to strongly agree; we have modified this in order to be consistent with the order of the rest of the questions in our survey, which range from positive to negative responses. The higher the number of points, the greater the degree of presenteeism (symptoms of illness while working). The mean score for presenteeism will be calculated in the intervention and control groups; the mean differences in the two groups will be compared, along with a 95% CI. | Approximately 90 days | |
Secondary | Reduction in ARI/ILI/GI Infections among those at Highest Risk for Complications as Self-Reported in Questionnaire | Analysis will be performed on a sub-set of employees who respond affirmatively to a question, which inquires if participants have been diagnosed with one or more listed chronic conditions. The conditions increase the risk of complications from ARI/ILI or GI infections. The content in the measurement item to assess the number of ARI/ILI/GI infections has demonstrated acceptable validity and reliability in a previous study from a scale that does not have a formal title, utilized by Stedman-Smith, DuBois and Grey (2012). The scale measures whether or not participants have had self-reported (1) ARI/ILI or (2) GI infections using definitions from the CDC. Survey measurements will occur at baseline and weekly for 12 weeks. The number of self-reported infections during the 3-month trial will be counted, combined, and summed in the intervention and control groups; incidence rates and an incident rate ratio will be calculated with a 95% CI. | Approximately 90 days | |
Secondary | Improvement in Hygiene Behaviors as Self-Reported in Questionnaire | Survey items will be measured at the baseline; middle and conclusion of the study. Improvement in self-reported hand hygiene behaviors will be measured by a construct of seven items; the construct was part of a survey that does not have a formal title, which demonstrated acceptable validity and reliability from previous research by Stedman-Smith et al. (2012). The items contain a scale of 5 rankings from always (1) to never (5). Higher scores indicate more protective practices. Improvement in the use of hand sanitizer disinfectant wipes will be measured by a newly created item that measures the self-reported frequency of usage on a scale of 0-5, ranging from 2 or more times a day (5) to never (0). Higher scores indicate more protective self-reported hygiene practices. Mean scores will be calculated in the intervention group and in the control group and the two groups will be compared by mean differences. | Approximately 90 days | |
Secondary | Improvement in Hygiene-Related Attitudinal Beliefs as Self-Reported in Questionnaire | Measurement will occur at the baseline; middle and end of the study. Survey items measure constructs on a scale of 1-5 from strongly agree to strongly disagree: perceived beliefs about the benefits of performing protective hygiene behaviors; perceived employer and co-worker norms about hygiene behaviors; and perceived control beliefs about performing hygiene behaviors. Higher scores indicate stronger positive beliefs. Six of the nine constructs have demonstrated acceptable validity and reliability in a survey that does not have a formal title, created by Stedman-Smith et al. (2012). Three items were created regarding the use of disinfectant surface wipes and perceptions about environmental cleanliness. All survey items consist of a scale from 1-5, ranging from strongly agree (1) to strongly disagree (5). Higher scores indicate more positive beliefs. Mean scores will be calculated in the intervention and control groups, and mean differences will be compared. | Approximately 90 days |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03943654 -
Improving Nighttime Access to Care and Treatment (Part 2)
|
||
Completed |
NCT05269290 -
Efficacy and Safety of Ingavirin®, Syrup, 30 mg/5 ml, in Children With Influenza and Other Acute Respiratory Viral Infections
|
Phase 3 | |
Completed |
NCT06385821 -
A Study to Prove Non-inferior Immunogenicity of Grippol Quadrivalent Compared to Grippol Plus
|
Phase 3 | |
Not yet recruiting |
NCT05902702 -
Isotonic Saline for Children With Bronchiolitis
|
N/A | |
Not yet recruiting |
NCT04525118 -
Wide Scale Monitoring for Acute Respiratory Infection Using a Mobile-based Study Platform
|
||
Completed |
NCT01431469 -
Efficacy and Tolerance of a Follow-On Formula Fed to Children From 12-48 Months of Age in Salvador, Bahia, Brazil
|
N/A | |
Completed |
NCT00981513 -
Direct and Indirect Benefits of Influenza Vaccination in Schools and Households
|
Phase 4 | |
Recruiting |
NCT06183229 -
Cycloferon for Post-exposure Prophylaxis of Acute Respiratory Viral Infections and Influenza
|
Phase 3 | |
Completed |
NCT03274310 -
FluSAFE: Flu SMS Alerts to Freeze Exposure
|
N/A | |
Completed |
NCT03736096 -
Molecular Diagnosis of Respiratory Viral Infections on Sputum From Cystic Fibrosis Patients
|
||
Completed |
NCT03189537 -
Study of Post-Exposure Ingavirin® Prophylaxis of Influenza and Acute Respiratory Viral Infections
|
Phase 3 | |
Completed |
NCT03028077 -
Effects of GS-3K8 and GINst15 on Acute Respiratory Illness
|
N/A | |
Enrolling by invitation |
NCT01286285 -
Surveillance of Influenza in Paediatric Intensive Care Units in Bavaria
|
N/A | |
Completed |
NCT03840135 -
Efficacy and Safety of Polyoxidonium, Nasal and Sublingual Spray, 6 mg/ml in Children Aged 1-12 Years With ARI
|
Phase 3 | |
Completed |
NCT01488435 -
Efficacy and Tolerance of a Follow-On Formula Fed to Children From 36-48 Months of Age
|
N/A | |
Not yet recruiting |
NCT00545961 -
Middle Meatal Bacteriology During Acute Respiratory Infection in Children
|
Phase 4 | |
Completed |
NCT05273619 -
Efficacy and Safety of XC8, Film-coated Tablets, 40 mg in Patients With Dry Non-productive Cough Against Acute Respiratory Viral Infection
|
Phase 3 | |
Recruiting |
NCT04415827 -
Energy Supply in Athletes and Untrained Persons With Bronchopulmonary Diseases
|
N/A | |
Completed |
NCT03459391 -
Study to Assess Safety, Tolerability and Pharmacokinetics of XC221 in Healthy Volunteers
|
Phase 1 | |
Withdrawn |
NCT04938323 -
Prevention of Acute Respiratory Infection in Taiwanese Institutionalized Elderly
|
Phase 2/Phase 3 |